Results 81 to 90 of about 3,679,356 (272)

Epigenetics in diagnosis, prognostic assessment and treatment of cancer:An update [PDF]

, 2014
Cancer cells contain multiple genetic and epigenetic changes. The relative specificity of many epigenetic changes for neoplastic cells has allowed the identification of diagnostic, prognostic and predictive biomarkers for a number of solid tumors and ...
Briasoulis, Evangelos, Crook, Tim, Hatzimichael, Eleftheria, Lagos, Konstantinos, Sim, Van Ren   +4 more
core   +4 more sources

Inhibition of TOPORS ubiquitin ligase augments the efficacy of DNA hypomethylating agents through DNMT1 stabilization

Nature Communications
DNA hypomethylating agents (HMAs) are used for the treatment of myeloid malignancies, although their therapeutic effects have been unsatisfactory. Here we show that CRISPR-Cas9 screening reveals that knockout of topoisomerase 1-binding arginine/serine ...
Satoshi Kaito, Kazumasa Aoyama, M. Oshima, Akiho Tsuchiya, Makiko Miyota, Masayuki Yamashita, S. Koide, Yaeko Nakajima-Takagi, H. Kozuka-Hata, M. Oyama, Takao Yogo, T. Yabushita, Ryoji Ito, Masaya Ueno, Atsushi Hirao, Kaoru Tohyama, Chao Li, K. Kawabata, Kiyoshi Yamaguchi, Yoichi Furukawa, H. Kosako, Akihide Yoshimi, S. Goyama, Y. Nannya, Seishi Ogawa, K. Agger, Kristian Helin, Satoshi Yamazaki, Haruhiko Koseki, N. Doki, Yuka Harada, H. Harada, Atsuya Nishiyama, M. Nakanishi, Atsushi Iwama   +34 more
semanticscholar   +1 more source

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center

Frontiers in Oncology, 2021
Relapsed/refractory acute myeloid leukemia (AML) is a devastating disease with a poor prognosis and represents a major unmet medical need. We report on a real-world academic center experience of treating 25 patients with relapsed/refractory AML using ...
Matthew E. Tenold, Benjamin N. Moskoff, David J. Benjamin, R. Hoeg, A. Rosenberg, M. Abedi, J. Tuscano, B. Jonas   +7 more
semanticscholar   +1 more source

Beyond hypomethylating agents failure in patients with myelodysplastic syndromes [PDF]

Current Opinion in Hematology, 2014
Although hypomethylating agents (HMAs) significantly improve outcomes in myelodysplastic syndromes (MDS), only half the patients achieve objective responses, and most responders lose response within 1-2 years. Azacitidine prolongs survival by a median of only 9.5 months. Failure of HMA therapy is associated with a very dismal prognosis.
Amer M, Zeidan, Mohamed A, Kharfan-Dabaja, Rami S, Komrokji   +2 more
openaire   +2 more sources

Prognostic Impact of European LeukemiaNet Genetic Risk Stratification System in Adult Patients With Acute Myeloid Leukemia

Aging and Cancer, EarlyView.
This study aimed to evaluate the prognostic value of ELN2017 in predicting survival outcomes and to assess the impact of clinical and molecular factors such as age, FLT3 and NPM1 mutations, and allogeneic hematopoietic stem cell transplantation (allo‐HSCT).
Mobina Shrestha, Bishwas Mandal, Vishal Mandal, Asis Shrestha, Amir Babu Shrestha   +4 more
wiley   +1 more source

Clinical outcomes of venetoclax combined with hypomethylating agents versus hypomethylating agents alone in TP53-mutated myelodysplastic syndromes

Haematologica
Not available.
Mahmood Aldapt, Yu-Hung Wang, Kashish J. Shah, Mobachir El Kettani, James Foran, Mohamed Kharfan-Dabaja, Hemant Murthy, Aref Al-Kali, Mithun V. Shah, Hassan Alkhateeb, Antoine N. Saliba, William Hogan, Cecilia Arana Yi, Lisa Sproat, Nathan Punwani, Nandita Khera, Jeanne Palmer, Mark Litzow, Ayalew Tefferi, Naseema Gangat, Mrinal M. Patnaik, Talha Badar   +21 more
doaj   +1 more source

Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia

Blood neoplasia
Key Points • Octogenarians and nonagenarians with AML can be treated successfully with VEN-HMA, and a subset of patients (∼25%) have prolonged survival.• Reduced dosing duration may be appropriate in this population, adjusted on a patient-by-patient ...
E. Madarang, Jillian Lykon, Wei Zhao, M. Sekeres, Terrence Bradley, N. Chandhok, Justin Taylor, S. Venugopal, T. Koru-Sengul, S. Iyer, Jason S. Gilbert, Ryan M. Miller, J. Nanni, Irene Zacheo, Agnese Mattei, N. Al Ali, Ashwin Kishtagari, G. Marconi, D. Sallman, D. Pollyea, M. Savona, C. Papayannidis, R. Komrokji, Justin Watts   +23 more
semanticscholar   +1 more source

How I treat MDS after hypomethylating agent failure [PDF]

Blood, 2019
Abstract Hypomethylating agents (HMA) azacitidine and decitabine are standard of care for myelodysplastic syndrome (MDS). Response to these agents occurs in ∼50% of treated patients, and duration of response, although variable, is transient.
openaire   +3 more sources

Reduced Maintenance DNA Methylation Thresholds Enable Sensitive Reporter Assays for UHRF1 and DNMT1 Inhibition

Advanced Science, EarlyView.
The authors engineer colorectal cancer cells with reduced redundancy of UHRF1 and DNMT1, key DNA methylation maintenance factors, lowering the maintenance threshold and sensitizing cells to inhibition. They develop reporter assays driven by endogenous tumor‐suppressor gene promoters with enhanced sensitivity and dynamic range to demethylating drugs ...
Cuicui Xia, Ying Cui, Jiongliang Wang, Wenjing Bai, Danyang Wang, Yao Chen, Huahui Guo, Liangyi Zong, Bing Qin, Xintong Cai, Jie Wang, Jing Huang, Scott B. Rothbart, Zufeng Guo, Stephen B. Baylin, Xiangqian Kong   +15 more
wiley   +1 more source

Hypomethylating agents use in acute myeloid leukemia: A single-center experience

Indian Journal of Medical and Paediatric Oncology, 2020
Context: Acute myeloid leukemia (AML) is a heterogeneous disease. Approximately 80% of older AML patients will die of their disease or its treatment with currently available antileukemic therapy because of the adverse prognostic risk factors.
Sravan Kumar Bodepudi, Santhosh Kumar Devdas, Vinayak V Maka, Rasmi Palassery, Sumathi S Hiregoudar, Nalini Kilara   +5 more
doaj   +1 more source